Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Olanzapine

An atypical antipsychotic of the thienobenzodiazepine family, patented in 1991. Approved in the United States in 1996 for psychotic disorders, it is mainly used for schizophrenia and bipolar disorder. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It was born from the search for a 'cousin' of clozapine that would not need regular blood monitoring: chemists replaced one of its benzene rings with a thiophene ring.

OlanzapineGo to the active ingredient →
OlanzapineActive ingredientOlanzapineCat. No. P-O011-001CAS 132539-06-1
Olanzapine-d3Isotopically labelledOlanzapine-d3Cat. No. P-O011-011CAS 786686-79-1
Olanzapine-d8Isotopically labelledOlanzapine-d8Cat. No. P-O011-012CAS 1093380-13-2

EDQM standards 4

The official European Pharmacopoeia standards for this family.

Reference substanceOlanzapine CRSEDQM code Y0001370Family Olanzapine

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.